Genomind To Present New Results At ISCTM Autumn Conference On “Pharmacogenetic Testing In Psychiatric Populations”

Genomind To Present New Results At ISCTM Autumn Conference On “Pharmacogenetic Testing In Psychiatric Populations”

September 27, 2011 – Chalfont, Pennsylvania – Genomind, LLC, a company focused on neuropsychiatric personalized medicine, will present data from a new study at the 2011 Autumn Conference of The International Society for CNS Clinical Trials and Methodology (ISCTM).  The presentation will summarize methods, results, and conclusion for its study, “Does Pharmacogenetic Testing in Psychiatry Influence Clinician Treatment Selection and Confidence?” The Conference will be held at Amelia Island, Florida, on October 3-4, 2011.

“We are very pleased to present our new results at the prestigious ISCTM Conference, and to share information about clinicians using biomarker testing in their psychiatric practices,” said Jay Lombard, DO, Chief Scientific Officer for Genomind. “Our study will help inform an important discussion about the clinical use of patient genetic information to influence current trial-and-error approaches to treatment of psychiatric patients.”

ISCTM, The International Society for CNS Clinical Trials and Methodology, is a multi-disciplinary independent organization, devoted to promoting advances that address strategic clinical, regulatory, methodological, and policy challenges that arise in the development and use of central nervous system (CNS) therapeutics. The work is accomplished through partnerships with persons in academia, industry, government, policy-making, and the public. Learn more at www.isctm.org.

Genomind is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of personalized medicine into psychiatry by providing genetic information to better understand the patient. Its Genecept™ Assay was made available for the study. Genomind was founded by Ronald I Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health and bringing innovations in science, delivery, and access to mental health patients. He also is founder of ValueOptions, one of the nation’s leading behavioral health and wellness companies. Dr Lombard, a neurologist, is co-founder of Genomind and is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at www.genomind.com.

Contact:

Adam Shapiro
ASPR
202-427-3603
Adam.Shapiro@ASPR.bz

Amy Pressman
Marketing Manager, Genomind
267-532-8866
apressman@genomind.com